Under the terms of the services agreement, Galadeno will provide technology and adenoviral reagents that will enable Celera to validate potential drug targets. Galadeno will construct recombinant adenoviruses containing genes selected by Celera. The viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways, Galapagos said.
Galadeno will receive payments "related to its services and technology," Galapagos said, but further financial details were not disclosed.